Literature DB >> 30523511

Single-brand dual-chamber discriminators to prevent inappropriate shocks in patients implanted with prophylactic implantable cardioverter defibrillators: a propensity-weighted comparison of single- and dual-chamber devices.

Sem Briongos-Figuero1, Ana Sánchez2, M Luisa Pérez3, José B Martínez-Ferrer4, Enrique García5, Xavier Viñolas6, Ángel Arenal7, Javier Alzueta8, Nuria Basterra9, Aníbal Rodríguez10, Ignacio Lozano11, Roberto Muñoz-Aguilera2.   

Abstract

PURPOSE: Comparisons of the efficacy of dual- vs. single-chamber implantable cardioverter defibrillators (ICDs) in preventing inappropriate shocks have had contradictory results. We investigated whether dual-chamber devices have a lower risk of inappropriate shocks and the specific role of supraventricular tachycardia (SVT) discriminators.
METHODS: All heart failure (HF) patients without an indication for pacing and implanted with a prophylactic ICD were recruited from the nationwide multicenter UMBRELLA registry. Arrhythmic events were collected by remote monitoring and reviewed by a committee of experts.
RESULTS: Among 782 patients, single-chamber ICDs were implanted in 537 (68.7%) and dual-chamber devices in 245 (31.3%). During a mean follow-up of 52.2 ± 24.5 months, 109 inappropriate shocks were delivered in 49 patients (6.2%). In the propensity-score-matched analysis, dual-chamber ICDs were related to lower rates of inappropriate shocks as compared to single-chamber devices (0.9% vs. 11.8%, p = < 0.001, log-rank test). In multivariable Cox proportional analysis, independent predictors of inappropriate shock were history of atrial fibrillation (hazard ratio (HR) = 2.78, CI 1.37-5.64, p = 0.004), chronic kidney disease (HR = 6.15, CI 2.82-13.53, p < 0.001), and non-ischemic cardiomyopathy (HR = 2.84, CI 1.54-5.23, p = 0.001). Among ICD settings, PR logic was the only discriminator independently related to a reduced risk of inappropriate shocks (HR = 0.18, CI 0.06-0.48, p = 0.001), along with an SVT limit enabled over 200 bpm (HR = 0.24, CI 0.11-0.51, p < 0.001).
CONCLUSIONS: In this nationwide cohort of primary prevention ICD-only patients, dual-chamber devices were related to lower risk of inappropriate shocks compared to single-chamber ICDs. Besides, PR logic and SVT limit > 200 bpm emerged as protective factors.

Entities:  

Keywords:  Atrial fibrillation; Dual-chamber; Implantable cardioverter defibrillator; Inappropriate shock; PR logic

Mesh:

Year:  2018        PMID: 30523511     DOI: 10.1007/s10840-018-0494-0

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  27 in total

1.  Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study.

Authors:  Paul A Friedman; Robyn L McClelland; William R Bamlet; Helbert Acosta; David Kessler; Thomas M Munger; Neal G Kavesh; Mark Wood; Emile Daoud; Ali Massumi; Claudio Schuger; Stephen Shorofsky; Bruce Wilkoff; Michael Glikson
Journal:  Circulation       Date:  2006-06-12       Impact factor: 29.690

2.  Is dual-chamber programming inferior to single-chamber programming in an implantable cardioverter-defibrillator? Results of the INTRINSIC RV (Inhibition of Unnecessary RV Pacing With AVSH in ICDs) study.

Authors:  Brian Olshansky; John D Day; Stephen Moore; Lawrence Gering; Murray Rosenbaum; Maureen McGuire; Scott Brown; Darin R Lerew
Journal:  Circulation       Date:  2006-12-18       Impact factor: 29.690

3.  Critical analysis of dual-chamber implantable cardioverter-defibrillator arrhythmia detection : results and technical considerations.

Authors:  B L Wilkoff; V Kühlkamp; K Volosin; K Ellenbogen; B Waldecker; S Kacet; J M Gillberg; C M DeSouza
Journal:  Circulation       Date:  2001-01-23       Impact factor: 29.690

4.  Do current dual chamber cardioverter defibrillators have advantages over conventional single chamber cardioverter defibrillators in reducing inappropriate therapies? A randomized, prospective study.

Authors:  I Deisenhofer; C Kolb; G Ndrepepa; J Schreieck; M Karch; S Schmieder; B Zrenner; C Schmitt
Journal:  J Cardiovasc Electrophysiol       Date:  2001-02

5.  Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks.

Authors:  Eleanor B Schron; Derek V Exner; Qing Yao; Louise S Jenkins; Jonathan S Steinberg; James R Cook; Steven P Kutalek; Peter L Friedman; Rosemary S Bubien; Richard L Page; Judy Powell
Journal:  Circulation       Date:  2002-02-05       Impact factor: 29.690

6.  Dual chamber arrhythmia detection in the implantable cardioverter defibrillator.

Authors:  B Dijkman; H J Wellens
Journal:  J Cardiovasc Electrophysiol       Date:  2000-10

7.  Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms.

Authors:  Dominic A M J Theuns; A Peter J Klootwijk; Dick M Goedhart; Luc J L M Jordaens
Journal:  J Am Coll Cardiol       Date:  2004-12-21       Impact factor: 24.094

8.  Clinical experience with the new detection algorithms for atrial fibrillation of a defibrillator with dual chamber sensing and pacing.

Authors:  V Kühlkamp; V Dörnberger; C Mewis; R Suchalla; R F Bosch; L Seipel
Journal:  J Cardiovasc Electrophysiol       Date:  1999-07

9.  Experience with a dual chamber implantable defibrillator.

Authors:  Volker Kühlkamp; Bruce L Wilkoff; Amy B Brown; Kent J Volosin; B J Hügl; Wayne Stafford; Douglas A Cameron
Journal:  Pacing Clin Electrophysiol       Date:  2002-07       Impact factor: 1.976

10.  Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.

Authors:  Bruce L Wilkoff; James R Cook; Andrew E Epstein; H Leon Greene; Alfred P Hallstrom; Henry Hsia; Steven P Kutalek; Arjun Sharma
Journal:  JAMA       Date:  2002-12-25       Impact factor: 56.272

View more
  2 in total

1.  Long-Term Outcomes Among a Nationwide Cohort of Patients Using an Implantable Cardioverter-Defibrillator: UMBRELLA Study Final Results.

Authors:  Sem Briongos-Figuero; Arcadio García-Alberola; Jerónimo Rubio; José María Segura; Aníbal Rodríguez; Rafael Peinado; Javier Alzueta; José B Martínez-Ferrer; Xavier Viñolas; Joaquín Fernández de la Concha; Ignasi Anguera; María Martín; Laia Cerdá; Luisa Pérez
Journal:  J Am Heart Assoc       Date:  2020-12-25       Impact factor: 5.501

Review 2.  Successful Identification of and Discrimination Between Atrial and Ventricular Arrhythmia with the Aid of Pacing and Defibrillator Devices.

Authors:  Rahul K Mukherjee; Manav Sohal; Nesan Shanmugam; Simon Pearse; Fadi Jouhra
Journal:  Arrhythm Electrophysiol Rev       Date:  2021-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.